Clinical trials: MARS
Functional Dyspepsia
Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia
This study is a multi-center, randomized, active-controlled, double-blind, non-inferiority, phase III clinical trial evaluating efficacy and safety of once-daily mosapride (UI05MSP015CT) in patients with functional dyspepsia.
- Trial name
- NCT03225248
- Testing
- UI05MSP015CT, Gasmotin
- Volunteers
- 143 people
- Sponsor
- Korea United Pharm. Inc.
Primary Hypercholesterolaemia and Mixed Dyslipidaemia, Atherosclerotic Cardiovascular Disease
Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector
Primary objectives: To assess the effectiveness of the PRALUENT® 2 ml SYDNEY auto-injector as measured by the lipid-lowering effect of alirocumab after approx.
- Trial name
- MARS (NCT05129241)
- Where
- Germany
- Volunteers
- 163 people
- Sponsor
- Sanofi
Liver Failure
Recompensation of Exacerbated Liver Insufficiency With Hyperbilirubinemia and/or Encephalopathy and/or Renal Failure
The objective of this trial is to evaluate the impact of elimination of albumin bound substances during albumin dialysis (MARS®) on mortality and the clinical time course in patients with a recent severe clinical deterioration of…
- Trial name
- RELIEF (NCT00614146)
- Testing
- MARS device, Standard medical therapy
- Where
- 19 sites in Austria, Belgium and 7 more
- Volunteers
- 59 people
- Sponsor
- Vantive Health LLC
Mucopolysaccharidosis IV Type A, Morquio A Syndrome
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
The objectives of this program are: to characterize and describe the Mucopolysaccharidosis IV type A (MPS IVA) population as a whole, including the heterogeneity, progression, and natural history of MPS IVA; to evaluate the…
- Conditions
- Mucopolysaccharidosis IV Type A, Morquio A Syndrome, MPS IVA
- Trial name
- MARS (NCT02294877)
- Testing
- Vimizim® (elosulfase alfa)
- Where
- 79 sites in United States, Australia and 15 more
- Volunteers
- 418 people
- Sponsor
- BioMarin Pharmaceutical
Hepatic Encephalopathy, Liver Failure
Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
The primary objective of the study was to compare the efficacy, safety and tolerability of Extracorporeal Albumin Dialysis (ECAD) using the Molecular Adsorbent Recirculating System (MARS®) device in improving severe HE by 2…
- Conditions
- Hepatic Encephalopathy, Liver Failure, Hepatitis, Chronic, Liver Cirrhosis
- Trial name
- NCT00287235
- Testing
- MARS, Standard Medical Therapy
- Where
- 8 sites in United States, Belgium and 1 more
- Volunteers
- 70 people
- Sponsor
- Vantive Health LLC
Atherosclerosis, Coronary Artery Disease
MARS - Monitored Atherosclerosis Regression Study
The purpose of this study is to determine whether significant alterations in serum lipoproteins as provided by the drug lovastatin can substantially reduce atherosclerosis progression or even induce regression.
- Trial name
- NCT00116870
- Testing
- lovastatin
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- Merck Sharp & Dohme LLC
Extraterrestrial Habitation Systems, Lunar Surface Habitation
A Multiphase Operational and Environmental Assessment of Lunar Surface Habitation, Lunar Gateway Transit Systems, and Acceleration Pathways for Sustained Human Habitation of the Martian Surface
This study evaluates the operational, environmental, and habitation-system requirements for sustained human presence on the lunar surface, the performance of the Lunar Gateway as a transit and staging architecture, and the…
- Conditions
- Extraterrestrial Habitation Systems, Lunar Surface Habitation, Lunar Water-Ice Resource Assessment, In-Situ Resource Utilization (ISRU)
- Trial name
- LUMEN-HAB (NCT07546461)
- Testing
- Habitat Systems Evaluation, Water-Ice Resource Utilization Assessment, EVA and Mobility Operations
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Truway Health, Inc.